Literature DB >> 16926186

Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values.

Eisuke Inoue1, Hisashi Yamanaka, Masako Hara, Taisuke Tomatsu, Naoyuki Kamatani.   

Abstract

OBJECTIVE: To estimate the disease activity score (DAS)28-C-reactive protein (CRP) threshold values that correspond to DAS28-erythrocyte sedimentation rate (ESR) values for remission, low disease activity and high disease activity in patients with rheumatoid arthritis.
METHODS: DAS28 data were analysed using a large observational study (Institute of Rheumatology Rheumatoid Arthritis) database of 6729 patients with rheumatoid arthritis. Firstly, the relationship between the DAS28-ESR and the DAS28-CRP values was analysed. Secondly, the best DAS28-CRP trade-off values for each threshold were calculated using receiver operating characteristic (ROC) curves.
RESULTS: The correlation coefficient of ESR versus CRP was 0.686, whereas that of DAS28-ESR versus DAS28-CRP was 0.946, showing the strong linear relationship between DAS28-ESR and DAS28-CRP values. DAS28-CRP threshold values corresponding to remission, low disease activity and high disease activity were 2.3, 2.7 and 4.1, respectively. The sensitivity and specificity from the ROC curves were gradually reduced as DAS28 values became lower.
CONCLUSIONS: This study showed that DAS28-CRP and DAS28-ESR were well correlated, but the threshold values should be reconsidered. As the results were derived from only Japanese patients, it is essential to compare DAS28-CRP threshold values in people of other ethnic groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926186      PMCID: PMC1856019          DOI: 10.1136/ard.2006.054205

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

Review 1.  Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice.

Authors:  Hisashi Yamanaka; Shigeto Tohma
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

2.  Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.

Authors:  D M van der Heijde; M A van 't Hof; P L van Riel; L A Theunisse; E W Lubberts; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

3.  Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.

Authors:  J S Smolen; C Han; M Bala; R N Maini; J R Kalden; D van der Heijde; F C Breedveld; D E Furst; P E Lipsky
Journal:  Arthritis Rheum       Date:  2005-04

4.  Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.

Authors:  M E Weinblatt; E C Keystone; D E Furst; A F Kavanaugh; E K Chartash; O G Segurado
Journal:  Ann Rheum Dis       Date:  2005-11-24       Impact factor: 19.103

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

6.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

7.  Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study.

Authors:  J F Maillefert; B Combe; P Goupille; A Cantagrel; M Dougados
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

8.  Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis.

Authors:  Yuko Matsuda; Gurkirpal Singh; Hisashi Yamanaka; Eiichi Tanaka; Wako Urano; Atsuo Taniguchi; Terunobu Saito; Masako Hara; Taisuke Tomatsu; Naoyuki Kamatani
Journal:  Arthritis Rheum       Date:  2003-12-15

9.  Preliminary criteria for clinical remission in rheumatoid arthritis.

Authors:  R S Pinals; A T Masi; R A Larsen
Journal:  Arthritis Rheum       Date:  1981-10

10.  DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.

Authors:  Bert Vander Cruyssen; Stijn Van Looy; Bart Wyns; Rene Westhovens; Patrick Durez; Filip Van den Bosch; Eric M Veys; Herman Mielants; Luc De Clerck; Anne Peretz; Michel Malaise; Leon Verbruggen; Nathan Vastesaeger; Anja Geldhof; Luc Boullart; Filip De Keyser
Journal:  Arthritis Res Ther       Date:  2005-07-08       Impact factor: 5.156

  10 in total
  126 in total

1.  Morning stiffness of the joints is the sole predictor of short-term response to glucocorticoid treatment in active rheumatoid arthritis (RA).

Authors:  C Fiehn; S Kessler; K Müller
Journal:  Rheumatol Int       Date:  2011-09-21       Impact factor: 2.631

2.  Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice?

Authors:  Ole Rintek Madsen
Journal:  Clin Rheumatol       Date:  2011-09-29       Impact factor: 2.980

3.  Longitudinal Occurrence and Predictors of Patient-Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis: A Case-Control Study.

Authors:  Divya N V Challa; Zoran Kvrgic; Cynthia S Crowson; Eric L Matteson; Thomas G Mason; Clement J Michet; Daniel E Schaffer; Kerry A Wright; John M Davis
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-12-10       Impact factor: 4.794

4.  Myocardial Inflammation, Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography, Is Associated With Disease Activity in Rheumatoid Arthritis.

Authors:  Isabelle Amigues; Aylin Tugcu; Cesare Russo; Jon T Giles; Rachelle Morgenstein; Afshin Zartoshti; Christian Schulze; Raul Flores; Sabahat Bokhari; Joan M Bathon
Journal:  Arthritis Rheumatol       Date:  2019-02-28       Impact factor: 10.995

Review 5.  Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities.

Authors:  Kazuki Yoshida; Helga Radner; Arthur Kavanaugh; Yoon-Kyoung Sung; Sang-Cheol Bae; Mitsumasa Kishimoto; Kazuo Matsui; Masato Okada; Shigeto Tohma; Michael E Weinblatt; Daniel H Solomon
Journal:  Clin Exp Rheumatol       Date:  2013-10-03       Impact factor: 4.473

6.  Interchangeability of 28-joint disease activity scores using the erythrocyte sedimentation rate or the C-reactive protein as inflammatory marker.

Authors:  Liseth Siemons; Harald E Vonkeman; Peter M ten Klooster; Piet L C M van Riel; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2014-02-23       Impact factor: 2.980

7.  Serum level of neopterin is not a marker of disease activity in treated rheumatoid arthritis patients.

Authors:  Dalia El-Lebedy; Jihan Hussein; Ingy Ashmawy; Asmaa M Mohammed
Journal:  Clin Rheumatol       Date:  2016-10-03       Impact factor: 2.980

8.  [Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) : solo or duet?].

Authors:  J G Kuipers; L Köhler
Journal:  Z Rheumatol       Date:  2013-06       Impact factor: 1.372

9.  Patients with active rheumatoid arthritis but only few tender and swollen joints: a subgroup with impaired short term outcome.

Authors:  C Fiehn; S Kessler; W Drexler; H M Lorenz
Journal:  Rheumatol Int       Date:  2008-11-08       Impact factor: 2.631

10.  Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors.

Authors:  Hiroki Wakabayashi; Hitoshi Inada; Yosuke Nishioka; Masahiro Hasegawa; Akihiro Sudo; Kusuki Nishioka
Journal:  Clin Rheumatol       Date:  2016-12-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.